Predators trade All-Star Defenseman PK Subban to the Devils

Sports News Predators trade All-Star Defenseman PK Subban to the Devils

Glenn James/NHLI via Getty Images(NEW YORK) — The Nashville Predators have traded All-Star Defenseman P.K. Subban to the New Jersey for defenseman Steve Santini, defensive prospect Jeremy Davies, a 2019 second round pick and a 2020 second round pick, the teams announced.

Subban played for the Predators for the past three seasons after being traded from the Montreal Canadians in 2016.

The three time All-Star scored nine goals and assisted on 22 more in 63 games last season. In his career, the Canadian has 98 goals and 310 assists in 645 games.

“We appreciate P.K.’s contribution to the Predators and the Nashville community over the past three seasons, which have seen our organization have unprecedented success,” Predators general manager David Poile said in a statement. “He was an integral part of our run to the 2017 Stanley Cup Final, the 2018 Presidents’ Trophy and back-to-back Central Division titles. His work off the ice speaks for itself — he was an impactful member of our community, especially through the groundbreaking Blueline Buddies initiative.”

The 2013 Norris Trophy winner as the league’s best defenseman will join a team that has missed the playoffs seven of the past eight seasons.

The Devils picked center Jack Hughes with the number one pick in the NHL Draft on Friday.

New Jersey now has three number one overall picks on their team following the selection of Hughes. He joins Taylor Hall, the 2010 top pick, and Nico Hischier, the 2017 top pick.

Santini has played in 114 games over the past four seasons with New Jersey. He has tallied five goals and 21 points in his career.

Davies turned pro in April after playing three seasons at Northeastern University. He was a finalist for the Hobey Baker Award last season, given to the top college hockey player.

Copyright © 2019, ABC Radio. All rights reserved.

Posted On 22 Jun 2019

Scoreboard roundup — 6/21/19

Sports News Scoreboard roundup -- 6/21/19

iStock(NEW YORK) — Here are the scores from Friday’s sports events:

St. Louis 5, L.A. Angels 1


N.Y. Yankees 4, Houston 1
Boston 7, Toronto 5, 10 Innings
Cleveland 7, Detroit 6
Chicago White Sox 5, Texas 4, 10 Innings
Minnesota 8, Kansas City 7
Tampa Bay 5, Oakland 3
Seattle 10, Baltimore 9

N.Y. Mets 5, Chicago Cubs 4
Pittsburgh 2, San Diego 1
Washington 4, Atlanta 3
Miami 2, Philadelphia 1
Cincinnati 11, Milwaukee 7
San Francisco 11, Arizona 5
L.A. Dodgers 4, Colorado 2


Connecticut 86, Atlanta 76
Indiana 76, Chicago 69
Seattle 84, L.A. Sparks 62

Copyright © 2019, ABC Radio. All rights reserved.

Posted On 22 Jun 2019

Planned Parenthood hosts 20 presidential candidates to talk abortion rights

Win McNamee/Getty Images(COLUMBIA, S.C.) — Planned Parenthood’s forum on reproductive rights at the University of South Carolina on Saturday will offer the crowded Democratic presidential field an opportunity to directly address a topic that has emerged as one of the most contentious in the election cycle.

So far this cycle, the parade of 2020 Democrats, primarily led by the female candidates, has sought to reclaim the reins of this politically sensitive issue with proactive proposals following a spate of restrictive anti-abortion bills sweeping across conservative states. The “We Decide” forum, hosted by Planned Parenthood’s political arm, will include 20 of the 23 Democratic presidential candidates and purports to offer the presidential hopefuls an opportunity to wade into the debate over such issues as contraception, using federal funding for abortions and several states’ bans on abortions after a fetal heartbeat can be detected.

A recent Quinnipiac poll found that 60% of voters said abortion should be legal in all or most cases, with 28% saying abortion should be legal in all cases, matching the highest level of support since the question was first asked in 2004.

Only 13% of voters believe abortion should be illegal in the case of rape or incest.

“We have the American people on our side,” Dr. Leana Wen, president of Planned Parenthood, told ABC News last month. “Seventy-three percent of Americans support Roe vs. Wade as the law of the land, and none of us want our children to live in a world where they have fewer rights than we do. So if he wants to make this a 2020 issue, we will win.”

Students for Life of America and USC’s Advocates for Life plan to protest the event.

Copyright © 2019, ABC Radio. All rights reserved.

New drug for women with low sex drive gets FDA approval


(NEW YORK) — We’ve long seen advertisements for drugs like Cialis or Viagra, which help to improve sexual performance in men with erectile dysfunction. But on Friday, the U.S. Food and Drug Administration approved a new medication that will boost libido in women with low sexual desire, so that they too can have an enjoyable sex life.

“There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment,” said Dr. Hylton V. Joffe, director of the FDA’s Center for Drug Evaluation and Research’s Division of Bone, Reproductive and Urologic Products, in a press release.

The prescription drug, called Vyleesi, will be available to pre-menopausal women with hypoactive sexual desire disorder (HSDD), a condition characterized by chronically low or non-existent sexual desire, which often causes distress. Although HSDD isn’t often spoken about, as many as 10% of women may be affected by it.

“Clinicians don’t have a process for diagnosing and addressing it,” Dr. Sharon Parish, professor of medicine in clinical psychiatry at Weill Cornell Medical College, told ABC News. “It’s under-recognized.”

HSDD affects women of all ages, and there’s no clear understanding of why it happens, either. Lindsay, a woman in her 30s who asked that ABC News only use her first name, said that she was diagnosed with the condition at 22 years old.

“I had a very healthy sex drive through puberty that bottomed out when I tapered off of an anti-depressant,” she said. “I hopscotched between multiple OB-GYNs, female health specialists, three talk therapists and an acupuncturist.”

Lindsay, who participated in the trial for Vyleesi, said that she’s now on a “couple of medications that have helped me manage so that I can feel comfortable being intimate with my husband, even if it’s not something where I have spontaneous desire to do so.”

Vyleesi is not the first medication for improving women’s sexual desires. Addyi, a drug approved by the FDA in 2015, also improves women’s sexual desires by working kind of like an anti-depressant. However, earlier this year, the FDA issued new safety orders mandating that the drug’s labeling include a boxed warning — the agency’s strongest warning — after reports of concerning side effects, including severely low blood pressure and fainting, especially when used with alcohol.

Vyleesi offers an alternative option to Addyi. The injection drug meant to be used 25 to 40 minutes before sex — and lasting up to eight hours — showed statistically significant increases in sexual desire in women who used it during phase 3 clinical trials. The drug stimulates certain receptors in the brain that are believed to be integral to sexual functioning. There were also few side effects: nausea, headache and a mild increase in blood pressure (people with uncontrolled blood pressure should not be taking it).

Although an injection drug might turn some women off of using it, Dr. Carl Spana, president and CEO of Palatin Pharmaceuticals, which makes Vyleesi, said it shouldn’t be a concern because the needle is tiny — it comes as an injectable pen.

“In our trials, nobody stopped using Vyleesi because it was injectable,” Spana said.

Sue Goldstein, a clinical sexual educator and author of the book When Sex Isn’t Good, told ABC News about her HSDD and how she had been treated with Addyi successfully. She was also involved in coordinating clinical trials for the drug. She welcomed the new option for women, Vyleesi.

“My sexual life has returned to what it was when I was 25,” she said. “But to have another option is so wonderful. We meet a lot of women who have ‘duty sex’ to stay in a relationship or who are avoiding sex because they have no interest.”

There are no FDA-approved medications for menopausal women with HSDD. Palatin Pharmaceuticals told ABC News that while there is no pricing information yet, Vyleesi is expected to be available to the public in September.

Vanessa Cutler, M.D., is a resident physician in psychiatry at Rush University Medical Center and a member of the ABC News Medical Unit.

Copyright © 2019, ABC Radio. All rights reserved.